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ABSTRACT 
In Vitro and In Vivo Activation of the Pituitary-Adrenal Axis by 
Corticotropin-Releasing Factor, Vasopressin (VP), and Two VP 
Analogs. (August 1993) 
Jeffery A. Carroll, B. S. , Texas A&M University 
Chair of Advisory Committee: Dr. Thomas H. Welsh, Jr. 
This project's objectives were to: 1) compare the relative 
potency of a VP analog with that of CRF and VP in terms of ACTH 
secretion by cultured bovine corticotrophs; 2) evaluate a VP analog 
as an antagonist of VP-induced ACTH secretion by cultured bovine 
corticotrophs; 3) evaluate the ability of CRF and VP to induce ACTH 
secretion in vivo in cattle; and, 4) evaluate the ability of the 
antiglucocorticoid, RU486, to block the inhibitory effects of 
dexamethasone (DEX) on CRF- and VP-induced ACTH secretion in vitro. 
Bovine and porcine adenohypophyses were enzymatically 
dispersed to yield cells for primary culture. On Day 5 of primary 
culture, bovine and porcine corticotrophs were challenged for 3 h 
and 4 h, respectively, with medium alone (Control) or various 
combinations and concentrations of bCRF, VP, the two VP analogs, { 
VPB: [Deamino'(D-3-(Pyridyl) Alaz, Arga)-VP]; and VPP: [d(CHz)q, D- 
Try(Et)z, Val4, Cits-VP]f, DEX and RU486. Medium concentration of 
ACTH was determined by RIA. Bovine CRF, VP, and the VP analogs 
each increased (P & . 05) ACTH secretion by bovine corticotrophs. 
Maximal increases in ACTH secretion occurred in response to . 1P. M 
bCRF (S. l-fold) and 1PM VP (3. 7-fold), relative to Control. VP and 
VPB were more potent than VPP in terms of stimulating secretion of 
ACTH. RU486 and DEX, added either alone or together to bovine or 
porcine corticotrophs did not affect (P & . 10) basal concentration of 
ACTH. DEX reduced (P & . 01) CRF-stimulated secretion of ACTH by 
68%. Concurrent addition of RU486 negated 62% of the inhibitory 
effect of DEX on CRF-stimulated secretion of ACTH. 
Cows were randomly assigned to one of four groups (n = 8 
cows/group): 1) Control (saline); 2) bCRF (. 3 pg/kg BW); 3) VP (1 
gg/kg BW); and 4) bCRF (. 3 pg/kg BW) + VP (1 p, g/kg BW). Jugular 
blood samples were collected at 15-min intervals for 4 h pre- and 
for 6 h post-treatment; samples also were taken at 1, 5 and 10 min 
post-treatment. Plasma concentration of ACTH and cortisol did not 
differ among the groups for the 4-h pre- injection period. At 1 min 
post-injection, bCRF + VP, VP, and bCRF increased ACTH secretion 
22. 4-, 9. 6-, and 2. 2- fold respectively, relative to Control (. 03 
ng/ml). Maximal plasma concentration of ACTH occurred at 5, 10, 
and 15 min for VP (1. 02 ng/ml), bCRF + VP (1. 4 ng/ml), and bCRF (. 32 
ng/ml), respectively. 
These data demonstrate that the two VP analogs are agonistic 
ACTH secretagogues in vitro. RU486 partially blocks DEX's inhibition 
of ACTH secretion of ACTH in vitro. VP acutely activates the bovine 
pituitary-adrenal axis whereas the ACTH response mediated by CRF 
is slower in onset longer duration. 
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INTRODUCTION 
When an animal is exposed to a stressor, neurotransmitters are 
activated which mediate the secretion of corticotropin-releasing 
factor (CRF) and vasopressin (VP) by specific hypothalamic neurons. 
These two neurohormones (CRF and VP) stimulate the corticotrophs 
in the adenohypophysis to release adrenocorticotropic hormone 
(ACTH) which in turn stimulates the adrenal cortex to release 
glucocorticosteroids (cortisol and corticosterone; Figure 1). The 
secretion and plasma concentration of these stress-related 
hormones (e. g. , ACTH and cortisol) have been used as classical 
diagnostic tests or bioiogical endpoints to assess the functional 
integrity of the adrenal axis and/or characterize responsiveness to a 
stressor or stressful enviroment. 
Elevated cortisol (CS) in response to a stressor has long been 
associated with detrimental effects on reproduction and animal 
productivity (e. g. , average daily gain, milk production) and more 
recently with a compromised immune system. It has been estimated 
that shipping stress, a condition associated with increased secretion 
of ACTH and CS during transportation and marketing of beef cattle 
can be linked to approximately 80% of all feedlot deaths (McKercher, 
1978; Hutcheson and Cole, 1986) resulting in a loss of $700 million 
per year for the beef industry. 
Citations on the following pages follow the style of Journal of 
Animal Science. 
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In order to combat the detrimental biological and economic 
effects of stress, we must first identify and understand the factors 
that compromise the pathway of the hypothalamic-pituitary-adrenal 
axis (HPA). CRF and VP both stimulate the release of ACTH, however, 
the relative potency of these neurohormones is species specific. In 
cultured bovine corticotrophs, CRF is more potent, whereas in 
cultured ovine corticotrophs, VP is more potent. Recently, an analog 
of VP has been shown to be 1/36 as potent as VP in stimulating the 
release of ACTH by cultured ovine corticotrophs (Schwartz et al. , 
1991). The regulatory action of CRF and VP on the synthesis and/or 
secretion of CRF and/or VP is still under investigation. However, 
Aguilera et al. (1993) provided some insight when they reported that 
water deprivation-induced VP decreased CRF mRNA and increased the 
accumulation of CRF in the paraventricular nucleus of the rat. Apple 
et al. (1993) have also recently evaluated additional factors such as 
serum calcium and electrolytes in restraint-stressed sheep. 
Although there are several VP analogs available, (some reported to 
have antagonist activity peripherally) there has not been an analog 
reported which has antagonistic activity at the pituitary. 
Dexamethasone, however, has been utilized successfully to inhibit 
both CRF- and VP-induced release of ACTH (Wagner, 1987). 
Therfore, the objectives of this study were to: 
1) compare the relative potency of a VP analog with that of CRF 
and VP in terms of ACTH secretion by cultured bovine 
corticotrophs; 
2) evaluate a VP analog as an antagonist of VP-induced ACTH 
secretion by cultured bovine corticotrophs; 
3) evaluate the ability of CRF and VP to induce ACTH 
secretion in vivo in cattle; 
4) evaluate the ability of the antiglucocorticoid, RU486, to 
block the inhibitory effects of dexamethasone on CRF- and 
VP-induced ACTH secretion in vitro. 
LITERATURE REVIEW 
Background. The physiological consequences of stress on the 
body have been of scientific interest for many years. The first 
scientist to introduce the term "stress" into the medical community 
was Hans Selye during the 1930s. Selye proposed that regardless of 
the stimuli, the body would respond in the same physiological 
manner. Selye's work attracted the interest of several other 
scientists into this field of study who strived to link the endocrine 
system to the stress response of the body (Sapolsky, 1988). 
Early investigators concluded that the regulation of the 
secretion of glucocorticoids by the adrenal cortex depended on a 
linkage of the hypothalamus and pituitary gland. For example, Harris 
(1948), after studying factors which regulated the pituitary gland, 
suggested that neurons of the hypothalamus regulate the secretion of 
hormones from the adenohypophysis. Harris' findings led to further 
investigation into the hypothalamic-pituitary axis. In the 1950s, 
several others had provided convincing evidence that one of the 
factors produced in hypothalamic neurons regulated the secretion of 
adrenocorticotropic hormone (ACTH) from the adenohypophysis 
(Saffran et al. , 1955; Guillemin and Rosenberg, 1955; Porter and 
Jones, 1956). According to conventional nomenclature, Saffran et al. 
(1955) named this adenohypophyseal regulator corticotropin- 
releasing factor. 
During this same period, other scientists were conducting in 
vivo stress studies with VP in the rat (Martini and Morpurgo, 1955; 
I4cCann, 1957). Initially, VP was thought to be the putative CRF. 
This led to a controversy in the scientific community as to which 
substance, CRF or VP, was the primary factor responsible for the 
regulation of ACTH secretion. Throughout the 1960s and 1970s, the 
controversy continued, although there was increasing evidence that 
VP was indeed not the primary stimulator of ACTH secretion 
(Arimura et al. , 1967; Portanova and Sayers, 1973). 
In addition to CRF and VP, there are at least two other 
regulatory factors that have been reported to induce ACTH secretion 
from the adenohypophysis; epinephrine (E; Giguere and Labrie, 1983) 
and oxytocin (OT; Link et al. , 1993). The presence of high affinity 
receptors for both E (Petrociv et al. , 1983) and OT (Antoni, 1986) 
have been identified in the rat pituitary. However, the focus of this 
report will be on the CRF and VP-induced ACTH secretion. 
Localization of CRF and VP. Vale et al. (1981) characterized 
the chemical structure and sequenced ovine CRF as a 41-amino acid 
hypothalamic peptide with intrinsic ACTH-releasing activity. Land 
et al. (1982) isolated and sequenced the DNA complementary to the 
specific mRNA for vasopressin. Gillies et al. (1982) demonstrated 
that VP enhanced the ACTH-releasing potential of CRF. In women, Liu 
et al. (1983) demonstrated that VP and CRF acted synergistically in 
regard to stimulation of ACTH secretion. Eventually, with the use of 
immunohistochemical staining techniques, CRF was identified in 
various regions of the hypothalamus with the primary source 
localized in the parvocellular neurons of the paraventricular nucleus 
(PVN; Bugnon et al. , 1982; Merchenthaler et al. , 1982; Olschowka et 
al. , 1982; Figure 2). 
These CRF neurons can be subdivided into two types: 1) a VP- 
containing neuron and 2) a VP-deficient neuron. The axons which 
transport CRF from these neurosecretory cells originate in the 
medial parvocellular subdivision of the PVN and project to the 
external zone of the infundibulum in the tuberohypophyseal tract 
where CRF is released into extracellular space around the 
fenestrated capillaries of the hypothalamo-hypophyseal portal 
system (Guillaume et al. , 1992). Vasopressin has been localized in 
two regions of the hypothalamus, the magnocelllular neurons of both 
the PVN and the supraoptic nucleus (SON; Zimmerman et al. , 1977; 
Figure 2). The neurons that synthesize VP in the PVN and SON project 
their axons in the paraventriculohypophyseal and 
supraopticohypophyseal tracts, respectively, and terminate in the 
neural lobe of the neurohypophysis (Figure 3). 
The pathway by which magnocellular neuron synthesized VP 
reaches the corticotrophs in the adenohypophysis of the pituitary is 
still unresolved. Two of the most widely accepted viewpoints are 
provided by Holmes et al. (1986) and Oliver et al. (1977). Holmes et 
al. (1986) contend that VP is released from preterminal axons in the 
internal zone of the infundibulum. The other possible pathway 
proposed by Oliver et al. (1977) suggests that VP is transported by 
retrograde blood flow from the neurohypophysis to the portal system 
which facilitates delivery of VP to the adenohypophysis. 
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CRF and VP Receptors. As of 1984, there were two types of 
peripheral vasopressin receptors identified (i. e. , Vl and V2 
receptors). The Vl receptor is located on smooth muscle and liver 
cells. The V2 receptor, however, has been shown to be responsible 
for the antidiuretic activities induced by VP in the kidneys. Although 
the V2 receptor transduction signal is via the adenylate cyclase 
system, the Vl receptor does not seem to be mediated through this 
particular second messenger pathway (Knepel et al. , 1 984). 
Many scientists agreed with the theory of two separate VP 
receptors. The concept they did not agree upon, however, was which 
receptor was responsible for the CRF-like induced ACTH secretion. 
While some reported considerable evidence that the CRF-like activity 
of VP paralleled pressor potency (Mormede, 1983; Knepel et al. , 
1982), others had previously reported results which were in conflict 
with these findings (Doepfner et al. , 1963; Arimura et al. , 1969). 
Jard et al. (1988) provided more insight into this controversy when 
they suggested the presence of a pituitary vasopressin receptor with 
its own distinct form. They contended that this pituitary 
vasopressin receptor retained some of the Vl receptor properties 
and thus named it the Vlb receptor (Jard et al. , 1988). 
As molecular biologists continue their work to isolate and 
identify this and other possible VP receptors with CRF-like activity, 
endocrinologists and physiologists continue the task of learning how 
stress affects the body. 
The CRF receptor was identified in the brain (Wynn et al. , 1984) 
and the anterior pituitary (Leroux and Pelletier, 1984) of the rat. 
However, further investigation into the localization of CRF receptors 
has demonstrated the existence of the receptor in extra- 
hypothalamic tissues of the body (Herkenham, 1987). 
Mechanism of Action for CRF and VP. CRF and VP are both 
polypeptide hormones that bind to their respective membrane bound 
receptors in the pituitary gland (DeSouza et al. , 1985; Lutz-Bucher 
and Koch, 1983). Both receptors exhibit similiar properties in that 
they are desensitized and down-regulated in response to chronic 
stimulation by their specific ligand (Reisine and Hoffman, 1983; 
Koch and Lutz-Bucher, 1985). 
When CRF binds to its specific receptor, it activates protein 
kinase A which is coupled to adenylate cyclase to produce 3', 5' cyclic 
AMP (cAMP; Labrie et al. , 1982). VP on the other hand has been shown 
to activate protein kinase C and does not directly stimulate the 
production of cAMP. However, Abou-Samra et al. (1987) did report 
that VP would augment the production of cAMP in CRF-stimulated 
corticotrophs. 
It has been proposed, however, that increases in cAMP activate 
calcium channels in a variety of cells (Luini et al. , 1985; Armstrong 
and Eckert, 1987). In 1988, Luini and DeMatteis reported a study in a 
permeabilized corticotroph mouse pituitary tumor cell line (AtT-ZO), 
a homogenous ACTH-secreting cell line, that showed exocytotic 
release of ACTH is calcium dependent and that cAMP had no direct 
effect on ACTH release from corticotrophs. Also, it has been shown 
that stimulation of corticotrophs with both CRF and VP results in 
increased intracellular calcium. Stimulation with CRF results in a 
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calcium influx from cytosolic origin whereas VP mobilizes calcium 
from intracellular stores. Therefore, Link et al. (1993) postulated 
that it may be the release of intracellular pool of calcium which is 
the main regulatory signal that activates ACTH release irrespective 
of the secretagoges. 
ACTH and Corticotrophs. ACTH in the porcine, bovine, 
ovine, and human is a single-chain polypeptide that consists of 39 
amino acids (Evans et al. , 1966). The N-terminal amino acids 
numbered 1 through 24 are identical in each of the aforementioned 
species. This particular portion of the amino acid sequence is 
responsible for the full biological activity of the complete molecule. 
The major difference among species is in the C-terminus amino acids 
25-33. ACTH is synthesized in corticotrophs of the pars distalis of 
the adenohypophysis (Baker, 1974). 
Corticotrophs are classified as basophils due to their intense 
blue staining with aldehyde thionin and are diffusely distributed 
throughout the pars distalis. The percentage of all cells in the pars 
distalis that are corticotrophs is varible. However, most reports 
concur with Baker et al. (1969) that corticotrophs represent 4% of 
the cell population in the pars distalis. The corticotroph has been 
described as having: a cytoplasm of low electron opacity; sparse 
electron-opaque secretory granules approximately 200 mp in 
diameter in a single row beneath the cell membrane; immature 
granules in the Golgi apparatus separated from their enveloping 
membranes by a clear halo; slender mitochondria with cristae that 
are often parallel to the long axis of the cell; Golgi complexes 
scattered throughout the cytoplasm; and a modest amount of rough 
endoplasmic reticulum (Baker et al. , 1969). 
The identification of corticotrophs, however, is not a simple 
task. Other investigators have reported cell characteristics for the 
corticotroph that are inconsistent with the description by Baker et 
al. (1969). Kurosumi et al. (1962) described the corticotroph in the 
rat as having a dense core of secretory granules surrounded by a less 
dense zone and an outer limiting membrane. Also, according to 
Rennels and Shiino, the secretory granule in the corticotroph ranges 
from 126 to 154 mp. in diameter which is inconsistent with the 
report by Baker et al. (1974). 
Mechanism of Action for Dexamethasone. The exact mechanism 
by which cortisol and dexamethasone (DEX), a synthetic 
glucocorticoid, inhibit CRF- and VP-induced ACTH secretion remains 
elusive. It has been demonstrated by use of a clonal cell line that 
intracellular receptors mediate the actions of glucocorticoids by 
modulating nuclear events in corticotrophs (Svec, 1984). Two 
classes of glucocorticoid receptors (i. e. , Type I and Type II) have 
been reported (Canny et al. , 1990) in the central nervous system. The 
Type I receptors have a high affinity for aldosterone, corticosterone 
and cortisol, but not for DEX. The Type I receptors are concentrated 
in the hippocampus and dentate gyrus (Reul et al. , 1985). 
Type II glucocorticoid receptors are quite different as 
compared to the Type I receptors. Type II receptors are the classical 
DEX-binding receptors and are abundant in the hypothalamus and the 
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anterior pituitary where they are clearly implicated in the control of 
ACTH secretion (Dallman et al. , 1987). 
There have been several hypotheses as to what cellular 
event(s) is(are) mediated by DEX to directly inhibit secretion of 
ACTH by the corticotroph cells of the anterior pituitary. Reports on 
the effects of glucocorticoids on cAMP production are controversial 
(Link et al. , 1993). Also, the aforementioned studies reported in the 
section on mechanism of action for CRF and VP which refer to 
intracellular calcium involvement have recently been refuted (Clark 
and Kemppainen, 1993). Clark and Kemppainen (1993) have suggested 
that glucocorticoid negative feedback occurs at a step (s) prior to 
the influx of extracellular calcium. 
Glucocorticoid Receptors and RU486. Glucocorticoid receptors 
(GR) have been localized at multiple sites in the body including the 
hippocampus region of the brain, CRF producing neurons of the PVN 
and the anterior pituitary corticotrophs (Horiba et al. , 1993). These 
locations provide the pathway by which cortisol feeds back to the 
hypothalamus and the anterior pituitary to inhibit further CRF and 
VP-induced ACTH secretion. Recent results (Pacak et al. , 1993; 
Figure 1) suggested that glucocorticoids do indeed feedback to the 
PVN of the hypothalamus to inhibit the release of CRF and decrease 
hypothalamic turnover of catecholamines which are involved in 
regulation of CRF release. 
The search for an effective antisteroid which would block the 
negative feedback of glucocorticoids with high affinity for the GR 
led scientists from Roussel Uclaf to the discovery of RU38486 
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(RU486) or mifepristone. RU486 exhibits both antiprogestin and 
antiglucocorticoid properties, however, a higher dosage is required 
to achieve the antiglucocorticoid effect (Baulieu, 1986). Both, in 
vitro and in vivo studies demonstrate that, RU486 possesses GR 
blocking activity without exhibiting agonistic corticoid effects 
(Gagne et al. , 1985). The uniqueness of this particular antisteroid 
was that its affinity for the GR was three times greater than that of 
the synthetic glucocorticoid, dexamethasone. Experiments in humans 
and some animal models demonstrated that RU486 has the ability to 
block the inhibitory effect of CS on ACTH secretion in a dose-related 
manner (Spitz and Bardin, 1993). Sufficient evidence that may still 
be lacking however, is whether RU486 has the ability to block the 
negative feedback of CS on both CRF and VP-induced ACTH secretion 
especially in domestic farm animals. Therefore, development of an 
antistress agent would benefit the livestock industry. 
Consequences of Stress. The concept that stress imposes some 
detrimental effects on the body is not novel. One of the first adverse 
conditions associated with stress was the development of ulcers in 
experimentally stressed monkeys in the 1950s (as reviewed by 
Sapolsky, 1988). Even as early as the late 1960s, researchers were 
linking elevated levels of glucocorticoids to damage of the 
hippocampal cells of the brain (Sapolsky, 1988). Other adverse 
conditions that have been associated with stress include reduced 
rates of reproduction, lower production (e. g. , average daily gain, milk 
output) and a compromised immune system. 
The detrimental effects associated with reduced reproduction 
seem to be connected to the inhibition of the release of luteinizing 
hormone-releasing hormone (LHRH) from the infundibulum (Ono et al. , 
1984). In males, the inhibitory effect of cortisol on the secretion of 
luteinizing hormone (LH) and testosterone appears to be species 
dependent. Increased CS in the male rat (Vreeburg et al. , 1984), the 
bull (Welsh et al. , 1979), and man (Doerr and Pirke, 1976) has been 
reported to decrease both LH and/or testosterone. However, in the 
male Rhesus monkey (Hayashi and Moberg, 1987) and the boar (Liptrap 
and Raeside, 1975; Juniewicz and Johnson, 1981), increases in ACTH 
and/or CS are associated with an increase in plasma concentration of 
LH and testosterone. Although an increased plasma concentration of 
cortisol has been reported to have inhibitory effects in both males 
and females, it appears that females are more susceptible to stress. 
Some studies describe a greater stress-induced secretion of ACTH in 
females than in males. Moberg suggested that female reproduction is 
more susceptible due to the dependency of successful reproduction 
on carefully timed hormonal secretions (Moberg, 1991). If the female 
is subjected to stressors near the time of ovulation, the elevation of 
plasma cortisol can diminish the release of LHRH, this may inhibit 
the release/surge of LH from the adenohypophysis that is needed for 
ovulation. 
Reduced animal productivity and a compromised immune 
system are considered together for the purpose of this review. 
When an animal's immune system is compromised, it will usually 
become sick, and therefore, there is reduced production for that 
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animal [i. e. , lower average daily gain, lower milk yield, etc. (Friend, 
1991)]. In 1976, Selye described how stress affected not only the 
nervous and endocrine systems, but also the immune system (Selye, 
1976). Stress-induced effects on the immune system stem from the 
hormonal secretions of the hypothalamic-pituitary-adrenal axis 
(Livnat et al. , 1985). Several in vitro studies have demonstrated 
this connection by showing that CRF directly suppresses human 
peripheral blood natural killer cell activity (Pawlikowski et al. , 
1988) and monocyte chemotaxis (Stepien et al. , 1987). Also, when 
the immune system is suppressed due to stress, animals are more 
susceptible to conditions such as shipping fever/bovine respiratory 
disease (McKercher, 1978) and viruses that cause infectious bovine 
rhinotracheitis (Narita et al. , 1981). 
Summary. Previous studies provide ample scientific evidence 
to warrant further research regarding the endocrinology and 
physiology of "stress" in domestic animals. In order to efficiently 
combat the detrimental effects associated with stress, we must 
first have a thorough and complete understanding of how stress 
interacts with the body's nervous, endocrine, and immune systems. 
The intent of the proposed research was not to address all of these 
areas. The main focus of this thesis project was on the endocrine 
system. Therefore, the outlined objectives were proposed to gain 
further insight into the interactions of CRF and VP as activators of 
the stress response in cattle and how these factors may be negated. 
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MATER)ALS AND METHODS 
Experiment 1: In Vitro Regulation of CRF- and VP-induced ACTH 
Secretion 
Tissue. The pituitary glands were recovered from 30 
slaughtered steers, 2 heifers and 3 six-month old boars at the Texas 
ASM University Rosenthal Meat Sciences and Technology Center 
within 10-20 min following stunning of the animals. The tissues 
were transferred immediately to a tissue culture room in the 
adjacent Kleberg Center. After exsanguination, the head was 
removed at the occipitoatlantal joint and transferred to a processing 
room where a band saw was used to expose the brain. The brain was 
removed from the neurocranium to expose the pituitary gland. The 
pituitary gland was removed with a sterile scalpel and hemostats, 
placed in a sterile plastic bag, and then transferred immediately to 
the tissue culture room in the adjacent Kleberg Center. Upon arrival 
at the culture room, the pituitary gland was split mid-sagitally and 
separated under sterile conditions into the pars distalis of the 
adenohypophysis (PDA) and neurohypophysis (with pars intermedia). 
The pars distalis (see Appendix A for weights) was weighed and 
prepared for cell culture (Appendix 8); the weight of the 
neurohypophysis was recorded prior to disposal. 
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Ce/I Culture. The pars distalis was sliced into 1 mm thick 
sections with a Stadie-Riggs tissue slicer and placed into a 1X 
solution of Dulbecco's Modified Eagle Medium (DMEM) tissue culture 
medium until further processing. The slices were then minced into 
approximately 1 mm cubic portions with the blade of the tissue 
slicer and the pieces washed two times in 1X DMEM. Tissue from all 
steers, heifers and boars on a given culture day were pooled by 
species/sex class and enzymatically dispersed in 1X DMEM solution 
which contained 0. 3% collagenase (350 units/mg of tissue; Sigma 
Chemical Co. , St. Louis, MO) for 1 hour (37 &C water bath with the 
solution being mixed with a magnetic stir bar). After dispersal, the 
solution was filtered through a single layer of sterile gauze and the 
filtrate was then centrifuged for 15 min at 200 xg to precipitate the 
cells. The liquid was aspirated and the pellet of cells was 
resuspended in 1X DMEM and then centrifuged. This washing portion 
of the procedure was repeated three times. 
After the third wash, the cells were resuspended and the 
concentration of cells determined using a hemocytometer. Viability 
of the cells was assessed by trypan blue stain exclusion (viability 
averaged 7996). The cells were then diluted to a concentration of 
400, 000 viable cells/ml (200, 000 each for heifers and boars) in 1X 
DMEM containing 1. 0 M L-glutamine (Gibco Laboratories, Chagrin 
Falls, OH) and 10% fetal calf serum (Whittaker M. A. Bioproducts, Inc. , 
Walkerville, MD). The cell suspension was then dispensed in 1-ml 
fractions into 35 mm x 10 mm polystyrene 6-well tissue culture 
dishes (Corning Glass Works, Corning, NY. ) and placed into a 37 &C 
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incubator (95% humidified air and 5'%%d%%d carbon dioxide). The day of 
plating the cells was designated as Day 0 of the culture. 
On Day 2 (48 hours after plating cells), the medium was 
aspirated from the culture wells with sterile glass pipettes and a 
new 1 ml fraction of the supplemented 1X DMEM added to the well 
(medium was added gently to prevent dislodging of the cells from the 
culture wells). The medium was changed again on Days 3 and 4 as 
described above for Day 2. On Day 5, the cells were washed twice 
with serum-free medium prior to adding treatments. After the 
second wash, the medium was aspirated and a 1-ml fraction of 
serum-free 1X DMEM containing the treatment was added to the 
appropriate well and allowed to incubate for 3 h for primary cultures 
from the steers and the heifers, and 4 h for primary cultures from 
boars. After the 3-h and 4-h incubation periods, the medium was 
collected with plastic pipette tips, dispensed into polypropylene test 
tubes and stored at -20 &'C until medium concentration of ACTH was 
determined by radioimmunoassay (RIA) (Wagner, 1987). Primary cell 
cultures orginating from boar pituitaries had a new 1 ml fraction of 
1X DMEM plus serum added and continued in culture as described 
above until Day 14 at which time the cells were again treated as on 
Day 5 of the culture. After a 4-h incubation period, the medium was 
collected and analyzed as described above. 
Cell Culture Treatments. Dosages used for bCRF (Penninsula 
Laboratories, Inc. , Belmont, CA. , Cat. ¹8568), VP (Calbiochem, La 
Jolla, CA. , Cat. ¹676435) and DEX (Steraloids Inc. , Wilton, NH. , Cat. 
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¹P500) were based on previous results from our laboratory (Wagner, 
1987; Welsh et al. , 1989) and ranged from 10-» M to 10s M for CRF, 
10-s M to 10-s M for VP, and 10-io M to 10-7 M for the VP analog. In 
order to evaluate the efficiency of the two VP analogs (Figure 4) as 
potent agonists or antagonists at the level of the pituitary, dose 
concentrations were chosen to parallel those of the VPP analog 
(Manning et al. , 1992). The RU486 (17B-hydroxy-1 1 B- [4- 
dimethylaminophenyl-1]-1 7u [prop-1-ynyl]-estra-4, 9-diene-2-one) 
dose concentration chosen by our laboratory to evaluate its 
antiglucocorticoid effect was 10-s M (donated by Roussel-Uclaf). 
Ce/I Culture Medium. The cell culture medium was prepared by 
supplementing Dulbecco's Modified Eagle Medium with the following 
constituents: 1) 50 ml of 50X MEM; 2) 50 ml of 100X MEM non- 
essential amino acids; 3) 5 ml Fungizone (Amphotericin-B 250 
mg/ml); 4) 5 ml penicillin-streptomycin (10, 000 U/ml penicillin, 
10, 000 mg/ml streptomycin); 5) 18. 5 g HEPES (Gibco Laboratories, 
Chagrin Falls, OH); and 6) 18. 5 g sodium bicarbonate (Fisher 
Scientific, Fair Lawn, NJ). and 7) 5 ml of glutamine as an energy 
source. In order to sterilize the medium, it was passed through a 
filtration system fitted with a . 2 micron filter. 
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Experiment 2: In Vivo Activation of the Bovine HPA axis by bCRF and 
VP 
Animals and Plasma Samples. The ability of CRF and VP to 
enhance plasma concentration of ACTH was studied in eight docile, 
proestrous Jersey cows (500 kg BW and 6 yr old) at the Texas AlkM 
University Dairy Center. These particular cows had been exposed 
previously to extended periods of halter restraint and handling for 
teaching purposes. Blood samples were collected on four days during 
the experiment. Approximately 10 mls of blood were collected at 
each sampling time followed by an infusion of heparin (. 07 g/liter; 
Sigma, St. Louis, MO. , Cat. ¹H9133) and physiological saline (0. 9%) to 
replace fluid volume. 
Days 1 and 2 of the experiment were consecutive days after 
which the cows had a two-wk recovery period prior to the 
consecutive sampling on Days 3 and 4 of the experiment. Indwelling 
jugular cannulae were inserted in the cows 24 h prior to the onset of 
sample collection and remained intact for samples collected on the 
consecutive day. Blood samples were collected via jugular vein at 
15-min intervals for 4 h prior to treatment (PRE) and for 6 h after 
treatment (POST). Blood samples were also collected at 1, 5, and 10 
min POST. 
At time of treatment (Time 0), each cow received a 5-ml 
injection which consisted of one of the following four treatments in 
a saline vehicle: 1) Control (5 ml of saline alone; Control); 2) bCRF 
( 3 Pg/kg BW) 3) VP (1 ug/kg BW); and 4) bCRF ( 3 ILg/kg BW) + VP (1 
pg/kg BW). Cows were randomly assigned to treatment groups with 2 
24 
cows/treatment for each of the four treatment days. Days 1 and 2 
(Experiment 2a) were separated from d 3 and d 4 (Experiment 2b) in 
order to maintain the cows in the proestrous phase of the estrous 
cycle during all four days of the experiment. Blood samples were 
centrifuged (2820 xg) for 30 min at 4 oC at the Dairy Center to 
recover plasma which was then transferred to laboratory facilities 
in the Kleberg Center for analysis of ACTH and CS by RIA. 
in Vivo Treatments. To determine the ability of CRF and VP to 
induce secretion of ACTH in vivo, the cows were challenged with one 
of the following four treatments: 1) Control (saline alone); 2) 
bovine CRF (bCRF; 0. 3 pg/kg BW); 3) arginine vasopressin (AVP; 
1pg/kg BW); or 4) bCRF + AVP (0. 3 pg/kg BW and 1 u. g/kg BW, 
respectively). Each cow was evaluated with each of the four 
treatments on separate sampling days to allow for individual 
response variations. The experiment utilized cows in the proestrous 
phase of the estrous cycle; therefore, Experiments 2a and 2b were 
separated by at least 30 days. 
Radioimmunoassays. Cell culture medium and plasma from 
blood samples were used to determine the concentration of ACTH by 
using a modified version (Wagner, 1987) of a double antibody 
radioimmunoassay (Appendix C) developed by Nicholson et al. (1984): 
1) the first antibody was IgG-ACTH-1 rabbit anti-(1-24)ACTH (IgG 
Corporation, Nashville, TN) supplied at a dilution of 1:40 and diluted 
to 1:2000 for use; 2) the second antibody was goat anti-rabbit 
gamma-globulin (Calbiochem, La Jolla, CA. , Cat. ¹539845) diluted to 
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1:20; 3) &asl h(l-24)-ACTH (INC Biomedical, Carson, CA. , Cat. 
¹07106126) was reconstituted in double-distilled water to yield 
10, 000 cpm/100 pl and is used as the radioactive antigen, and 4) the 
standards were serially diluted (50 pg/100 Ij, l to . 0781 pg/100 P. l) 
from h(l-24)-ACTH (Peninsula Laboratories, Inc. , Belmont, CA. , Cat. 
¹8741). The primary antiserum does not crossreact with other 
peptides with a structure similar to that of ACTH (i. e. , lipotropin, 
melanotropin, or endorphin). In addition, hormones used in these 
experiments (i. e. , vasopressin, CRF, dexamethasone) do not interfere 
with the ability of the antiserum to bind radiolabeled ACTH. The 
sensitivity of the ACTH RIA was 2 pg/tube and the intra- and inter- 
assay coefficients of variation were 6 and 10%, respectively. The 
total volume of unknown assayed was 200 pl; the plasma or medium 
samples containing a higher quantity of ACTH needed to be diluted 
with assay buffer. 
Plasma samples were also assayed for CS using a primary 
antibody assay procedure (Appendix D) with the following 
components (Anderson et al. , 1986): 1) primary antibody was rabbit 
anti-cortisol antiserum received at a dilution of 1:400 and diluted 
further to 1:2500 (Pantex, Santa Montica, CA. , Cat. ¹P44); 2) the 
standards (4-pregnen-11B, 17, 21-triol-3, 20-dione; Steroids Inc. , 
Wilton, NH. ) were made by serial dilutions (4000 pg/500 p, l to 3. 9 
pg/500 p. l); 3) the tracer used was &H-Hydrocortisone (1, 2-~H; NEN, 
Boston, MA. , Cat. ¹NET-185) and 4) the liquid scintillation fluid was 
Ecolume (ICN, Irvine, CA. , Cat. ¹882470). The assay sensitivity was 
62 pg/assay tube and the antibody crossreacted 60, 48, 0. 01 and 
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0. 01% with corticosterone, deoxycorticosterone, progesterone and 
estradiol, respectively. Intra- and inter-assay coefficients of 
variation were 8 and 1296, respectively. 
Statistical Analysis. The concentration of ACTH and cortisol in 
unknowns was determined using the computer program Assay Zap 
(Biosoft, Cambridge, UK. ) which utilizes a four parameter model [ y= 
a-d/1+(x/c)~ + d ]. All in vitro and in vivo data were arrayed and 
analyzed by Excel 4. 0 (Microsoft Corporation) and Statview 1. 04 
(Abacus Concepts, Inc. , Berkley, CA. ). The Excel program was used to 
calculate means and the area under the hormone profile curves. 
Statview tests included in the analyses were: 1) unpaired T-test; 2) 
analysis of variance; 3) Fisher's r to z correlations; 4) Spearman's 
test for correlations; and 5) stepwise regression for prediction 
equations. The ANOVA models included time, culture replicate and 
interactions as sources of variation. Treatment differences with a P 
value less than or equal to . 05 were considered statistically 
significant. Correlation analyses were used to describe temporal 
relationships between ACTH and cortisol. 
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RESULTS AND DISCUSSION 
Experiment 7: ln Vitro Regulation of CRF and VP-induced ACTH 
Secretion 
CRF-induced ACTH Secretion. Five individual primary pituitary 
cell cultures were established from the 30 steers, as described in 
the Materials and Methods section, to investigate the ACTH releasing 
activity of bovine CRF. The following data are based on the 
treatment mean plus the standard error of the mean (S. E. M. ) for 6-8 
wells/culture. Figure 5 represents the stimulatory action of various 
concentrations of CRF (10-» M to 10-7 M). Secretion of ACTH by cells 
treated with 10-sM CRF did not differ (P & . 10) from that of Control 
cells (284. 9 g 14. 9 pg/ml). 
Secretion of ACTH was increased by treating cells with 10-a M 
CRF (3. l-fold increase; P & . 0001 relative to Control). Medium 
concentration of ACTH was further enhanced (P & . 0001) by treatment 
with 10-r M CRF (1577. 5 ~ 98. 6 pg/ml; a 5. 5-fold increase relative to 
Control). These results differ from those reported by Wagner (1987) 
in which ovine CRF-induced secretion of ACTH was increased by 2. 2- 
, 3. 3-, and 3. 7-fold, at 10-s M, 10-a M, and 10-7 M, respectively. A 
possible explanation for the diffences reported between the 
stimulatory effects of bovine and ovine CRF in cultured bovine 
corticotrophs may reside in the recognition of the ligand by the CRF- 
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Figure 5. Ability of CRF to stimulate ACTH secretion by 
steer anterior pituitary cells (400, 000 viable cells/well). 
Cells challenged on Day 5 of culture for 3 h (n = 6 
wells/treatment/culture). 
binding protein (i. e. , CRF BP). In a recent study, Woods et al. (1993) 
demonstrated that ovine CRF does not bind appreciably with human 
CRF BP and therefore does not dimerize to form the CRF-CRF BP 
complex which may be associated with the clearance rate of the 
ligand. The cells which synthesize the CRF BP have not been 
identified at this time. Therefore, the possible presence of these 
CRF binding proteins in our culture system could explain the 
different degrees of ACTH secretion in response to ovine versus 
bovine CRF. If the ovine CRF is not being bound by CRF BP with an 
affinity equivalent to that for bovine CRF, it would be reasonable to 
assume that there is more ligand that can interact with its receptor. 
Gibbs and Vale (1983) reported CRF concentration in the 
hypothalamic-hypophyseal portal blood of the rat to be 
approximately 1 ng/ml. In the ovine, Engler et al. (1989) reported 
that basal CRF concentration in the hyppophysial-portal circulation 
ranged from 18 g 8 pmol/I to 127 g 14 pmol/I. Given that in vitro 
studies for both the bovine and rat corticotroph demonstrate that 
CRF is a more potent stimulator of ACTH secretion than VP, it is 
possible that the concentration of CRF in the hypothalamic- 
hypophyseal portal blood of the bovine would be within the 1 ng/ml 
range. These levels are consistent with the reported Kd of CRF. 
Therefore, the stimulatory action of CRF 10-a M may indeed be 
physiologically relevant in the bovine. 
VP-induced ACTH Secretion. The stimulatory action of VP was 
also examined at various concentrations (10-'o M to 10-s M) as 
represented in Figure 6. Neither 10-&o M, 10-s M nor 10-a M increased 
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Figure 6. VP-induced ACTH secretion by cultured 
steer anterior pituitary cells (400, 000 viable cells/well). 
Cells challenged on Day 5 of culture for 3 h (n = 6 
wells/treatment/culture). 
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terms of stimulating secretion of ACTH. Medium concentration of 
ACTH was further enhanced (P & . 001) with 10-s M VP (1115. 45 g 79. 4 
pg/ml). 
The coupling of these data ( e. g. , comparison of CRF- and VP- 
induced secretion of ACTH) with the data of Wagner (1987), 
indisputably demonstrates that CRF is indeed the more potent 
stimulator of ACTH secretion in cultured bovine corticotrophs. The 
minimum stimulatory concentration of VP (10-7 M) is similar to the 
concentration reported in the hypothalamic-hypophyseal portal blood 
of the sheep (50-2000 pmol/liter; Engler et al. , 1989), the monkey 
(11-16 ng/ml; Zimmerman et al. , 1973), the rat (1 ng/ml; Gibbs and 
Vale, 1983) and in the horse (25 pmol/liter; Alexander et al. , 1991). 
ACTH Secretion Induced by 1/P Analogs. Both VPB AND VPP have 
been reported to possess antagonistic activity peripherally. At the 
onset of the present study it was known that the VPB analog also 
demonstrated agonistic activity at the pituitary in terms of 
stimulating ACTH secretion. We evaluated whether the VPP analog is 
an antagonist to VP at the level of the pituitary gland. We 
determined that VPP is an agonist rather than an antagonist to VP at 
the level of the pituitary. Figure 7 represents a comparison of VP 
with two analogs of VP (i. e. , VPP and VPB; see Materials and Methods 
for details). Relative to Control, medium concentration of ACTH 
increased for cells treated with 10-7 M VP, VPP and VPB. At 
equilmolar concentration (10 r M), VP and VPB were more potent than 
VPP in terms of stimulating secretion of ACTH. At 10-s M, the VPP 
analog tended to be less effective (P & . 05) than 10-s M VP. 
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Figure 7. Stimulatory action of VP and two VP analogs 
at various concentrations in steer anterior pituitary cell 
cultures. Cells (400, 000 viable cells/well) were 
challenged on Day 5 of culture for 3 h (n = 6 
wells/treatment/culture). 
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medium concentration of ACTH relative to Control (P & . 10). At 10. 7 
M, the stimulatory action of VP was apparent with a 2. 5-fold 
increase (P & . 0001) over Control (284. 9 ~ 14. 9 pg/ml). At an 
equimolar concentration of 10-7 M CRF was more potent than VP in 
Interestingly, the results obtained by treating the cells with 
the VPB analog do not concur with the potency report for this analog 
as compared to VP (Schwartz et al. , 1991) in sheep. Schwartz 
demonstrated that VPB was only 1/36 as potent as VP in terms of 
stimulating secretion of ACTH in sheep. The present results, 
however, demonstrate that in cultured bovine corticotrophs the ACTH 
stimulating ability of VPB is equivalent to VP at 10-7 M. The 
dissimilarity in the activity of VPB in these two studies is 
especially interesting given that VP is more potent in terms of 
stimulating secretion of ACTH by ovine corticotrophs. The 
discrepancy in the action of this analog may stem from the existence 
of receptor subtypes (e. g. , Vl, Vlb and V2; Jard et al. , 1988). It is 
conceivable that in the pituitary of the sheep there is a greater 
concentration of the Vlb subtype receptor, compared to the bovine 
pituitary. 
Time Course of CRF- and I/P-induced ACTH Secretion. To 
determine the temporal aspect of CRF- and VP-induced secretion of 
ACTH by cultured bovine anterior pituitary corticotrophs, the cells 
were challenged for 15, 30 or 120 min with medium alone, each 
neurohormone alone or a combination of the two neurohormones 
(Figure 8). By 15 min post-challenge, VP (10-s M), CRF (10-7 M) and 
the combination of CRF + VP each enhanced (P & . 05) medium 
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Figure 8. Temporal profile of ACTH secretion induced 
by CRF, VP and the combination of CRF + VP in steer 
anterior pituitary cell culture (400, 000 viable cells/well). 
Cells were challenged on Day 5 of culture for either 15, 
30 or 120 minutes. 
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cells treated with either CRF or VP alone. By 30 min post-challenge, 
secretion of ACTH induced by CRF (10-7 M) and VP (10-s M) were 
equivalent (P & . 10). However, medium concentration of ACTH for 
cells treated with the combination of CRF and VP was greater (P & 
. 05) than the medium concentration of ACTH for cells that were 
treated with either CRF or VP alone. 
By 120 min post-challenge, medium concentration of ACTH for 
the cells treated with the combination of CRF and VP increased 3. 3- 
fold relative to Control and was greater than (P & . 001) medium 
concentration of ACTH for cells treated with CRF and VP alone. 
There was no difference (P & . 10) in medium concentration of ACTH 
for cells treated with CRF or VP alone. The 180 min post-challenge 
secretion of ACTH is represented in Figure 5 for CRF and Figure 6 for 
VP. By 180 min post-challenge, the stimulatory action of VP had 
reached a plateau whereas CRF continued to increase medium 
concentration of ACTH and surpassed (P & . 001) the stimulatory 
action of VP. 
These results demonstrate that the onset of VP action or 
response to VP is more acute than that of CRF and tends to plateau 
after 120 min. The stimulatory action of CRF however is slow 
initially but continues to increase medium concentration of ACTH 
beyond the stimulatory action of VP. Similar temporal profiles of 
plasma concentration of ACTH were observed when the two 
neurohormones were evaluated in vivo (see Figures 14 and 15). 
Recently, other investigators (Cantor et al. , 1993) have also reported 
similar temporal profiles for CRF- and VP-induce B-endorphin in 
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concentration of ACTH relative to Control (541. 6 ~ 61. 8 pg/ml). 
Medium concentration of ACTH was greater (P & . 05) at 15 min for 
VP-treated cells relative to the CRF-treated cells. At 15-min, the 
medium concentration of ACTH was greater (P & . 05) for the cells 
treated with the combination of CRF and VP relative to those 
perifused ovine anterior pituitary cells. There are at least two 
factors that could account for these temporal differences: 1) CRF 
and VP activate separate and different second messenger systems 
(i. e. , protein kinase A and protein kinase C, respectively) and 2) the 
mechanism(s) involved in transport of these two neurohormones is 
different. 
Oex-induced Inhibition of ACTH Secretion. The ability of the 
synthetic glucocorticoid, DEX, to suppress protein kinase A (CRF) 
mediated secretion of ACTH is represented by Figure 9. Addition of 
10-s M DEX alone to the cultured cells did not affect (P & . 10) medium 
concentration of ACTH relative to Control (284. 9 ~ 14. 9 pg/ml). 
Addition of CRF increased secretion of ACTH (P & . 0001) 5. 5-fold 
relative to Control. Concurrent treatment with DEX decreased CRF- 
induced secretion of ACTH by 52%. 
The ability of DEX to inhibit protein kinase C mediated 
secretion of ACTH is represented by Figures 10 and 11. Medium 
concentration of ACTH was increased (P & . 0001) by treating cells 
with VP, VPB and VPP (10-s M each). Medium concentration of ACTH 
was enhanced 3. 9-fold each for VP and VPB, and 2. 2-fold for VPP 
relative to Control (284. 9 ~ 14. 9 pg/ml). Concurrent treatment with 
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0 - DEX (10 M) 
~ + DEX (10 M) 
a, b, c (P c . 004) 
a 
CONTROL VP (10 M) CRF ( 10 M) 
Figure 9. Dexamethasone's inhibition of CRF- and 
VP-induced ACTH secretion by cultured steer anterior 
pituitary cells (400, 000 viable cells/well). Cells were 
challenged with CRF, VP and/or DEX for 3 h on Day 5 
of culture (n = 6 wells/treatment/culture). 
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0 - DEX 
~ + DEX (10 M) 
a, b (P c . 06) 
a, c (P c . 0003) 
c, d (P c . 05) T 
b, c 
t 
t 
CONTROL VPP (10 M) VPB (10 M) VP (10 M) 
TREATMENTS 
Figure 10. Ability of DEX to suppress protein kinase C 
mediated ACTH secretion induced by VP and the two 
VP analogs (i. e. , VPP and VPB) in steer anterior 
pituitary cell cultures. Cells (400, 000 viable cells/well) 
were challenged on Day 5 of culture for 3 h (n = 6 
wells/treatment/culture). 
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C3 - RU486 
~ + RU486 
1500 
CONTROL DEX (10 M) CRF (10 M) CRF + DEX 
Figure 11. Ability of the antiglucocorticoid RU486 to 
negate the inhibitory effect of DEX on CRF-induced 
ACTH secretion in steer anterior pituitary cell culture. 
Cells (400, 000 viable cells/well) were challenged on 
Day 5 of culture for 3 h (n = 6 wells/treatment). 
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DEX decreased VP-, VPB-and VPP-induced secretion of ACTH by 32%, 
2196 and 44%, respectively. 
It has been demonstrated previously that CRF action is 
mediated via the protein kinase A system and VP action is mediated 
via the protein kinase C system (Abou-Samra et al. , 1987; Wagner, 
1987). Present results indicate that the inhibitory action of the 
synthetic glucocorticoid (e. g. , DEX) is expressed in both the protein 
kinase A and protein kinase C mediated ACTH secretion by cultured 
bovine corticotrophs. However, total suppression of the stimulatory 
action of CRF and VP in terms of ACTH secretion is not achieved with 
DEX. Although the mode of action of DEX remains elusive, it appears 
to block futher secretion of ACTH, but does not negate the previous 
stimulatory effects on the cell. 
RV486 Negation of the Inhibitory Effects of DEX. The ability of 
the antiglucocorticoid (RU486) to block the inhibitory effect of DEX 
on CRF-induced ACTH secretion by bovine and porcine anterior 
pituitary corticotrophs is presented in Figures 11 and 12. Addition 
of 10-s M RU486 or co-treatment with 10-& M DEX did not affect (P & 
. 10) medium concentration of ACTH relative to Control (267. 5 g 25. 8 
pg/ml). An 8. 5-fold increase (P & . 0001) in medium concentration of 
ACTH occurred in response to treatment with 10-7 M CRF. Co- 
treatment with CRF plus DEX suppressed medium concentration of 
ACTH by 68. 196. However, when RU486 was added to the combination 
treatment of CRF plus DEX, RU486 was able to negate 62% of the 
inhibitory effect of DEX. 
6000 
0 - RU486 
~ + RU486 
CONTROL OEX (10 M) CRF (10 M) CRF + DEX 
Figure 12. Ability of RU486 to negate the inhibitory 
action of DEX on CRF-induced ACTH secretion in 
porcine anterior pituitary cell culture. Cells (200, 000 
viable cells/well) were challenged for 4 h on Day 5 of 
culture (n = 6 wells/treatment). 
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The mechanism of action for RU486 at the glucocorticoid 
receptor remains elusive (Spitz and Bardin, 1993). The ability of 
RU486 to negate the suppressive action of DEX in porcine anterior 
pituitary corticotrophs is presented in Figure 12. Addition of 10-& M 
RU486 or co-treatment with 10-s M DEX did not affect (P & . 10) 
medium concentration of ACTH relative to Control (1605. 6 z 103. 6 
pg/ml). A 3. 2-fold increase (P & . 0001) in medium concentration of 
ACTH occurred in response to treatment with 10-7 M CRF relative 
toControl. Co-treatment with CRF plus DEX suppressed medium 
concentration of ACTH by 66%. Forty-two percent of this 
suppression was negated however when RU486 was added to the 
combination treatment of CRF plus DEX. 
The ability of RU486 to block the inhibitory action of DEX on 
CRF-induced secretion of ACTH in the bovine and porcine clearly 
demonstrates its antiglucocorticoid activity on anterior pituitary 
cells in vitro. Subsequent in vitro studies are in progress to 
evaluate the action of RU486 on the hypothalamus and infundibulum 
for both bovine and porcine tissues. Also, in vivo studies are being 
designed to investigate the ability of RU486 to inhibit the effects of 
DEX in the bovine. 
Experiment 2: Activation of the Bovine HPA Axis by bCRF and VP In 
Vivo 
In Vivo Experimental Design. There was no interaction (P & . 05) 
between effects of day of experiment and treatment; therefore, 
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values reported represent the means and S. E. M. for treatments pooled 
over all four days of the experiment. Standard error of the means are 
not represented to enhance the clarity of the graphs depicting the in 
vivo response to CRF and VP. There were no differences (P & . 10) 
among treatment means for any of the discrete time periods during 
the PRE period. Therefore only 1 h of the 4 h PRE period is 
illustrated in graphs along with representatives for the 6 h POST 
per lod. 
Control (Saline) Group. There was no difference (P & . 05) in 
plasma concentration of ACTH among cows (n = 8 cows) that received 
the saline alone treatment during the 4-h PRE period. At Time 0, 
cows were given a 5 ml injection of physiological saline. Saline 
injection had no affect (P & . 05) on plasma concentration of ACTH 
during the 6-h POST period (Figure 13). Therefore, the remaining 
treatment groups will be compared to Control. The mean plasma 
concentration of ACTH for all cows pooled over PRE and POST periods 
averaged 28. 2 g 1. 6 pg/ml. 
bCRF Treatment Group. During the PRE period plasma 
concentration of ACTH did not differ (P & . 10) among cows assigned 
to the bCRF treatment group (Figure 14). At Time 0, the bCRF 
treatment group did not differ (P & . 05) from Control. At 1 min POST, 
plasma concentration of ACTH was increased 2. 2-fold over Control 
(32. 7 ~ 7. 2 pg/ml) in cows challenged with bCRF. At 5 min POST, 
plasma concentration of ACTH was further increased 5-fold relative 
to Control. Maximal observed plasma concentration of ACTH (324. 8 ~ 
126. 2 pg/ml) was at 15 min POST. After 15 min POST, plasma 
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concentration of ACTH continually declined until 60 min POST at 
which time plasma concentration of ACTH for cows challenged with 
bCRF did not differ (P & . 05) from that observed for Control cows. 
VP Treatment Group. At Time 0, the VP treatment group did not 
differ (P & . 05) from Control. Although an acute difference (P & . 01) 
resulting from the VP challenge (9. 6-fold increase) was detected as 
early as 1 min POST relative to Control (Figure 15). At 5 min POST, 
plasma concentration of ACTH was increased 35. 5-fold relative to 
Control. Maximal plasma concentration of VP-induced ACTH 
secretion was observed at 5 min POST. The decline in VP-induced 
ACTH secretion was continuous after 5 min POST, however, it did not 
decline as rapidly as it had increased. At 60 min POST, the 
stimulatory effects of VP were no longer evident and plasma 
concentration of ACTH did not (P & . 05) differ from Control. 
bCRF plus l/P Treatment Group. At Time 0, the bCRF plus VP 
treatment group did not differ (P & . 05) from Control. Plasma 
concentration of ACTH for cows challenged with a combination of 
bCRF plus VP reflected not only an acute (within 1 min) response but 
also a prolonged (greater than 120 min) elevated plasma 
concentration of ACTH (Figures 16 and 17). At 1 min POST, plasma 
concentration of ACTH was increased Z2. 4-fold relative to Control 
(32. 7 ~ 7. 2 pg/ml). Maximal plasma concentration of ACTH (1399. 8 g 
Z60. 1 pg/ml) occurred at 10 min POST. Although the decline in 
plasma concentration of ACTH was continuous after 10 min POST, it 
remained elevated above Control for an additional 110 min. 
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The enhancement in plasma concentration of ACTH due to 
treatment with bCRF plus VP is consistent with the synergistic 
reports by Liu et al. (1983) in humans, Rivier et al. (1984) in the rat 
and Pradier et al. (1986) in sheep. The temporal aspects associated 
with plasma concentrations of ACTH observed for cows during the in 
vi vo portion of this study are undoubtly supported by the 
aforementioned in vitro results. Also, these data correspond to the 
real-time observations reported by Cantor et al. (1993) for ovine 
tissue. Other in vivo studies evaluating VP-induced secretion of 
ACTH in the bovine are not available at this time for direct 
independent comparisons of the in vivo action of VP. 
Plasma Concentration of Cortisol. An increase in plasma 
concentration of ACTH preceded the increase in plasma concentration 
of CS (Figures 13 through 16) irrespective of secretagogue. Areas 
under the hormone response curves (AUC) were calculated for plasma 
concentration of both ACTH and CS. Areas were utilized for 
correlation analysis during the PRE (PRE AUC) and POST (POST AUC) 
periods. Responsiveness of ACTH and CS (i. e. , POST AUC) were 
tightly coupled (r = . 71, P & . 0001). Cortisol POST AUC was 
positively correlated with CS PRE AUC ( r . 59, P & . 0003) but not 
with PRE AUC for ACTH (r = -. 31, P & . 08). Plasma concentration of 
CS at 0 min was lowly correlated with POST AUC for CS (r = . 32, P & 
. 08) and peak CS ( r = . 23, P & . 21). 
These data provide insight regarding the dynamics of ACTH and 
CS responsiveness to CRF and VP. These two neurohormones, CRF and 
VP, may be used to assess the pituitary-adrenal capacity in cattle. 
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However, due to the acute, transient response of ACTH and CS to the 
VP challenge, it is necessary that the sample collection window be 
narrower. Also, these hypothalamic neurohormones may be used in 
provocative tests to predict and(or) rank cattle with respect to 
relative secretion of ACTH and CS during stress-free periods. 
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IMPLICATIONS 
The pituitary-adrenal axis in the cow can be stimulated by the 
independent action of the endogenous neurohormones CRF and VP. 
Although VPP and VPB have been reported to be antagonists of VP in 
peripheral tissue, they both exert agonist activity on the bovine 
anterior pituitary. Our in vitro studies confirm that CRF is more 
potent than VP in terms of stimulating secretion of ACTH in the 
bovine corticotroph; however, direct in vivo comparisons of potency 
have not been reported at this time for cattle. 
There is a consistent and profound difference in acute and 
protracted ACTH response to CRF and VP in vitro and in vivo. 
Although CRF and VP mediate secretion of ACTH via two separate 
second messenger systems (protein kinase A and protein kinase C, 
respectively) the ACTH response induced by the combination of CRF 
and VP has both an acute phase and an extended response. Therefore, 
an animal's response to an exteroceptive stimulus, (e. g. , an acute 
response versus an extended response) is the consequence of 
integrated crosstalk between the protein kinase A and protein kinase 
C pathways. 
Further in vivo studies need to be conducted to confirm that 
bCRF rather than VP is the more potent stimulator of ACTH secretion 
in cattle. The present results from in vitro experiments suggest 
that CRF is the more potent stimulator of ACTH secretion in vivo; 
however, this remains to be established. It would also be relevant to 
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evaluate both VPP and VPB in vivo given the dual agonistlantagonist 
activities of these VP analogs. 
The initial results obtained with the antiglucocorticoid, 
RU486, need to be expanded to gain further insight into the hormonal 
mechanism(s) by which this antisteriod blocks DEX-induced 
suppression of CRF-induced secretion of ACTH. The ongoing studies 
evaluating the activity of RU486 at the levels of the hypothalamus 
and infundibulum should provide further insight into the sites of 
action of this antiglucocorticoid. 
Additional studies to quantitate the concentration of CRF and 
VP in portal blood of cattle during a physiologically stressful 
situation, such as during transportation, need to be undertaken. Also, 
there needs to be further investigation of the V1b subtype receptor 
and interactions between CRF and VP involved in the regulation of VP 
and CRF receptors. Finally, evaluation of genetic and gender 
diffences in the HPA axis of cattle needs to be addressed. 
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APPENDIX A 
Pars Distalis Weights 
Species Sex Class Slaughter Weight (Ibs) Pars Distalis (g) 
bovine 
bovine 
bovine 
bovine 
bovine 
bovine 
bovine 
bovine 
bovine 
bovine 
bovine 
bovine 
bovine 
bovine 
bovine 
bovine 
bovine 
bovine 
bovine 
bovine 
bovine 
bovine 
bovine 
bovine 
bovine 
bovine 
bovine 
bovine 
bovine 
bovine 
bovine 
bovine 
porcine 
porcine 
porcine 
steer 
steer 
steer 
steer 
steer 
steer 
steer 
steer 
steer 
steer 
steer 
steer 
steer 
steer 
steer 
steer 
steer 
steer 
steer 
steer 
steer 
steer 
steer 
steer 
steer 
steer 
steer 
steer 
steer 
steer 
cow 
cow 
boar 
boar 
boar 
1 580 
1524. 5 
1 500 
1 830. 5 
1550. 5 
1431 
11 34. 5 
1281 
1573. 5 
1163. 5 
1175. 5 
1371 
1088 
1221 
1359 
1119. 5 
1123. 5 
1424 
1133 
1050 
1168 
1221 
975 
1175 
855 
855 
787 
914 
918 
811 
1100 
1060 
167 
210 
203 
1. 5003 
1. 4479 
1. 4248 
1. 7392 
1. 4730 
1. 3594 
1. 0494 
1. 1544 
1. 6149 
1. 4403 
1. 1845 
1. 5351 
1. 3179 
1. 7578 
1. 3121 
1. 2902 
1. 6933 
1. 7670 
1. 4389 
1. 1380 
1. 3961 
1. 1960 
1. 0852 
1. 2297 
0. 6521 
0. 6317 
0. 8693 
1. 0036 
0. 8872 
0. 8941 
1. 2080 
0. 9740 
0. 1 879 
0. 1720 
0. 1780 
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APPENDIX B 
PITUITARY CELL CULTURE PROCEDURES 
A. Cell Culture Methodology 
Animals are humanely stunned and decapitated. After 
exsanquitation, the head is removed at the 
occipitoatlantal joint and transferred to a processing 
room where a band saw is used to expose the brain. 
The brain is removed to expose the neurocranium to 
expose the pituitary gland. The pituitary gland is 
removed with a sterile scalpel and hemostats, placed in a 
sterile plastic bag, and transferred immediately to the 
tissue culture room. 
3. The pituiary gland is spit mid-sagitally and separated 
under sterile conditions in a laminar flow hood into the 
pars distalis of the adenohypophysis and neurohypophysis 
(with pars intermedia). 
The pars distalis is weighed and then sliced into 1 mm 
thick sections with a Stadie-Riggs tissue slicer. The 
slices are placed into a 1X solution of Dulbecco's Modified 
Eagle Medium (DMEM) tissue culture medium until further 
processing. 
The slices are minced into 1mm cubic portions with the 
blade of the tissue slicer and then washed two times in 
1X DMEM. 
Pieces are placed in sterile 125-ml Erelenmyer flasks 
(approximately 2 pars distalis/flask) containing 75 ml 
DMEM with . 3% collagenase (350 units/mg tissue). The 
flasks are immersed into a 37&C water bath and agitated 
with a magnetic stir bar for 1 hour. 
After dispersal, the solution is filtered through a single 
layer of sterile gauze. The filtrate is then dispensed into 
50-ml centrifuge tubes and centifuged at 200 xg for 15 
min to precipitate the cells. 
The liquid is aspirated and the pellet of cells is 
resuspended in 50-ml of 1 X DMEM and then centrifuged. 
This washing procedure is repeated three times. 
After the third wash, the pellet of cells is resuspended in 
20 ml of 1X DMEM. 100 pl of the cell suspension is 
pipetted into a sterile polypropylene tube containing 100 
p, l of trypan blue stain. The stained cell solution is then 
pipetted into a hemacytometer chamber. 
10. Concentration of viable cells is determined by counting 
the number of non-stained cells on the grid and inserting 
this number into the following equation: 
(desired concentration of cells/ml) 
11. The cells are the diluted to a concentration of 400, 000 
viable cells/ml (200, 000 each for heifers and boars) in 
1X DMEM containing 1. 0 M L-glutamine and 10% fetal calf 
serum. 
12. The cell suspension is then dispensed in 1-ml fractions 
into 35 mm x 10 mm polystyrene 6-well tissue culture 
dishes and placed into a 37&C incubator (95% humidified 
air and 596 carbon dioxide. 
13. The day of culture establishment is considered to be Day 
0 and spent medium is replaced with 1 ml fraction of 
supplemented 1X DMEM on Days 2, 3 and 4 (medium is 
added gently to the inner side wall to prevent dislodging 
of the cells). 
14. On Day 5, the cells are washed twice with serum-free 
medium and appropriate treatments added. The volume 
serum-free medium added is 1 ml minus 50 ml multiplied 
by the number of treatments added to a particular well. 
The final total volume in each well is 1 ml. 
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15. After the appropiate incubation period, 3-h for steers and 
4-h for cows and boars, the medium is collected in 
plastic pipette tips, dispended into polypropylene tubes 
and stored at -200C until medium concentration of ACTH 
is determined by RIA. 
B. Cell Culture Medium, Collagenase and Viocase 
1. 
a 
Cell Culture Medium 
To prepare 1 liter of 5X DMEM, add the contents of 5 
one-liter packages of DMEM to approximately 800 mls of 
doubled distilled water. 
Then add 50 ml each of 50X MEM amino acids with L- 
glutamine and 100X MEM non-essential amino acids 10 
mM. 
To this solution add 5 ml each of Funfizone 
(Amphotericin-8 250 mg/ml) and penicillin-streptomycin 
(10, 000 U/ml penicillin, 10, 000 mg/ml streptomycin). 
Dissolve 18. 5 g each of sodium bicarbonate and HEPES 25 
mM and then pH solution to 6. 8. After appropriate pH is 
obtained, adjust final volume of solution to 1 liter. 
Solution is then sterilized by passing through a filtration 
system equipped with a . 2 micron filter and store at 40C. 
Filtering solution will raise the final pH to approximately 
7. 0). 
d. To prepare 500 ml of 1X DMEM, add 100 ml of 5X DMEM to 
400 ml sterile double distilled water and store at 40C 
until day of culture at which time the medium should be 
heated in a water bath to 37'C. 
The supplemented cell culture medium is prepared by 
adding 5 ml of L-glutamine and 50 ml of fetal calf serum 
to 445 ml of the 1X DMEM. This solution may also be 
stored at 4oC, but should be heated to 37oC before using 
in the cell culture. 
2. 
a 
Preparation of Collagenase 
To prepare 150 ml of collagenase solution, dissolve 450 
mg of collagenase in 150 ml of 1X DMEM and stir with a 
magnetic stir bar until completely dissolved. 
Filter solution by passing through a . 45 micron filter 
system attached to a vaccum. 
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c. The solution can then be sterilized by passing through a . 2 
micron filter attached to a vaccum. This will provide 
enough collagenase solution to dissociate approximately 
4 grams of tissue. 
3. Preparation of Viocase solution 
a. To prepare 100 ml of the viocase solution, add 20 ml of 
double distilled water to a bottle of pancreatin 10X 
(25g/liter) and vortex. 
b. Add 10 ml of the pancreatin solution to 90 ml of 1X DMEM. 
c. To sterilize, pass solution through a . 2 micron filter 
system attached to a vaccum. 
APPENDIX C 
ACTH ASSAY PROCEDURES 
A. Assay Methodology 
Day 1 (During the entire procedure keep all tubes on ice or 
at 4K). 
Add 200 pl Buffer 8 to N tube in triplicate. 
Add 100 pl Buffer B to 0 tube in triplicate. 
C. 
d. 
e. 
Add 100 pl of standard or unknown to appropriately 
labelled polypropylene tubes. 
Add 100 pl of first antibody to all tubes except the N and 
T tubes and vortex. 
Incubate for 24 hours at 4K. 
Z. 
a. 
Day 2 
Add 100 pl of »sl-ACTH to all tubes, T tubes in 
triplicate and vortex. 
Incubate for 72 hours at 40C. 
3. 
a 
Day 5 
Add 100 pl of second antibody to all tubes except the T 
tubes. 
Incubate for 4 hours at 4K 
Add 1. 6 ml of cold separation buffer to each tube except T 
tubes and centrifuge immediately for 20 min at 6000 x g. 
Decant supernatant and blot tubes on absorbent paper. 
Make sure that tubes are maintained at 4K or in ice 
water bath during this portion of the procedure. 
Count precipitate for 2 min on gamma counter. 
B. Assay Solutions 
l. 
a 
Buffer A 
For 1 liter of Buffer A, dissolve 16. 84 g of NazHPO4, 4. 74 
g of NazEDTA and . 2 g NaNs in approximately 800 ml of 
deionizied distilles water. 
Adjust volume to 1 liter and pH with 1 M NaOH to 7. 4. 
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2. Buffer 8 
a. For 400 ml of Buffer 6, combine 400 pl of Triton x-100 
and 10 ml of Trasylol with 400 ml of Buffer A. This will 
provide enough Buffer 6 for approximately 800 tubes. 
3. Buffer C 
a. Buffer C is used for diluting the first antibody, therefore 
the amount needed depends on the number of assay tubes. 
Buffer C is made by adding 2% normal rabbit plasma to 
Buffer B. 
4. Buffer D 
a. Buffer D is used for reconstituting the first antibody and 
is made by adding 1% normal rabbit plasma to Buffer A. 
5. Separation buffer 
a. To make 2 liters of Separation buffer, add 50 g of 2. 5% 
bovine serum albumin to 2000 ml of Buffer A. 
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APPENDIX D 
CORTISOL ASSAY PROCEDURES 
A. Assay Methodo/ogy 
a. 
b. 
C. 
d. 
Sample preparation 
Pipet 50 p, l of sample into appropriately labelles glass 
tubes. 
Add 450 pl of PBSG to each tube and vortex. 
Cork tubes and place in 700C water bath for 1 hour. 
Allow samples to cool down to room temperature and 
then proceed with setting up the assay. 
a. 
b. 
C. 
d. 
Setting up assay 
Pipet 500 pl of standard into appropriately labelled glass 
tubes in triplicate. 
Add 100 Ij, l of antibody to all tubes except the T and N 
tubes. 
Add 100 Ij, l of trace to all tubes and vortex. 
Allow to incubate at 4K for 12 to 18 hours. An 
alternative method is to allow to incubate at room 
temperature for 1 hour then transfer to 40C for 3 hours. 
3. 
a. 
b. 
C. 
d. 
Day 2 
Add 5 ml of Ecolume cocktail to mini-vials and label 
caps for vials. 
This portion of the procedure should be carried out in the 
cold room at 4K. Make sure charcoal is thoroughly mixed 
and add 200 '. l of the charcoal to all tubes except the T 
tubes. Shake racks of tubes and allow to set for 15 min. 
Centrifuge for 10 min at 2282 x g. Put tubes on ice or 
place in cold room immediately after centrifuging. 
Decant supernatant into the mini-vials and count each 
vial for 1 min in beta counter. 
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B. Assay Solutions 
1. PBSG 
a. To make 1 liter of PBSG, dissolve the following 
chemicals in 900 ml of double distilled water: 8. 17 g of 
NaCI, . 856 g of NaHzPO4, . 54 g of NazHPOq, 3. 72 g EDTA and 
. 1 g thimersal. 
b. Adjust pH to 7. 4. 
c. Add 1 g of gelatin to a 1 liter bottle and then add the 
EDTA-PBS from part b to the bottle. 
d. Dissolve gelatin mixture in a magnetic stir/hot plate 
while heating at a low to moderate temperature for 
approximately 2 hours. 
e. After cooling to room temperature the PBSG is ready to 
use. Store remaining PBSG at 4K. 
Z. Charcoal solution 
a. Combine . 0625 g of Dextran Pharmacia T-70 with . 625 g 
of Charcoal Norit SPXX and 100 ml of PBSG in a 200 ml 
beaker and mix with a magnetic stir bar. Store at 4&&C for 
up to two weeks. 
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